CVSG.L

CVS Group Plc
CVS Group plc - Exercise of Options and Total Voting Rights
28th June 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2504U
CVS Group plc
28 June 2024
 

28 June 2024

CVS Group plc

("CVS" or the "Company")

Exercise of Options and Total Voting Rights

CVS, one of the UK's leading providers of integrated veterinary services, confirms that certain employees have exercised options during June under the CVS Group 2020 SAYE Plan (2020/2024) totalling 11,345 ordinary shares of 0.2 pence each ("Ordinary Shares").

The issuance of shares in connection with the SAYE Exercise was partially satisfied by 481 Ordinary Shares held by the CVS Group Employee Benefit Trust (the "EBT").  Following the SAYE Exercise, a total of 164 Ordinary Shares are held by the EBT, representing approximately 0.0002% of the Company's total voting rights.

The sum of 10,864 new Ordinary Shares were issued to partially satisfy the balance of Ordinary Shares arising from the SAYE Exercise.  Admission of the 10,864 new Ordinary Shares has been satisfied by the Company's block listing admitted to the London Stock Exchange on 30 December 2021. 

Following the issue of these new Ordinary Shares, which rank pari passu in all respects with the Company's existing Ordinary Shares, the Company has a total issued share capital of 71,732,133 Ordinary Shares, each carrying one voting right. The Company holds no Ordinary Shares in treasury and the total number of voting rights is therefore 71,732,133.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Contacts:

CVS Group plc                                                                                                                                via Camarco

Richard Fairman, CEO

Scott Morrison, Company Secretary

 

Peel Hunt LLP (Nominated Adviser & Broker)                                                 +44 (0)20 7418 8900

Christopher Golden / James Steele / Andrew Clark / Lalit Bose

 

   Berenberg (Joint Broker)                                                                                          +44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

 

Camarco (Financial PR)                                                                                             

Geoffrey Pelham-Lane                                                                                +44 (0)7733 124 226

Ginny Pulbrook                                                                                                     +44 (0)7961 315 138

 





About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia.  CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group operates c.460 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties), Crematoria (providing pet cremation and clinical waste disposal for CVS and third-party practices) and an online retail business ("Animed Direct").

 

The Group employs c.9,000 personnel, including c.2,400 veterinary surgeons and c.3,400 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRDGGDLUBDDGSR]]>
TwitterFacebookLinkedIn